Lichen planus: Difference between revisions
No edit summary Tag: visualeditor-wikitext |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Lichen planus | |||
| image = [[File:Lichen_Planus_(2).JPG|alt=]] | |||
| caption = Lichen planus on the wrist | |||
| field = [[Dermatology]] | |||
| synonyms = | |||
| symptoms = [[Itching]], [[rash]], [[purple]] [[papules]] | |||
| complications = [[Oral lichen planus]], [[scarring]] | |||
| onset = [[Middle age]] | |||
| duration = [[Chronic]] | |||
| causes = [[Autoimmune disease]] | |||
| risks = [[Hepatitis C]], [[genetic predisposition]] | |||
| diagnosis = [[Clinical diagnosis]], [[biopsy]] | |||
| differential = [[Psoriasis]], [[eczema]], [[lichen simplex chronicus]] | |||
| prevention = | |||
| treatment = [[Corticosteroids]], [[antihistamines]], [[phototherapy]] | |||
| medication = [[Topical steroids]], [[oral steroids]] | |||
| prognosis = Generally good, but can be chronic | |||
| frequency = 0.1% to 4% of the population | |||
}} | |||
== '''Alternate names''' == | == '''Alternate names''' == | ||
Actinic LP; Lichen planus actinus; Lichen planus subtropicus; Lichen planus tropicus; Lichenoid melanodermatitis; Summertime actinic lichenoid eruption | Actinic LP; Lichen planus actinus; Lichen planus subtropicus; Lichen planus tropicus; Lichenoid melanodermatitis; Summertime actinic lichenoid eruption | ||
== '''Definition''' == | == '''Definition''' == | ||
Lichen planus (LP) is an [[inflammatory]] disorder of the skin and mucous membranes with no known cause. It appears as [[Pruritic disorder|pruritic]], violaceous [[papule]]s and [[plaques]] most commonly found on the wrists, lower back, and ankles. | Lichen planus (LP) is an [[inflammatory]] disorder of the skin and mucous membranes with no known cause. It appears as [[Pruritic disorder|pruritic]], violaceous [[papule]]s and [[plaques]] most commonly found on the wrists, lower back, and ankles. | ||
[[File:Lichen Planus Fig7.tiff|left|thumb]] | |||
[[File:Lichen Planus Fig7.tiff|thumb]] | [[File:Atrophic lichen planus.jpg|left|thumb]] | ||
[[File:Atrophic lichen planus.jpg|thumb]] | [[File:Lichen planus on leg.JPG|left|thumb]] | ||
[[File:Lichen planus on leg.JPG|thumb]] | [[File:Lichen planus new photo to help for diagnosis.jpg|left|thumb]] | ||
[[File:Lichen planus new photo to help for diagnosis.jpg|thumb]] | |||
<youtube> | <youtube> | ||
title='''{{PAGENAME}}''' | title='''{{PAGENAME}}''' | ||
| Line 20: | Line 38: | ||
height=600 | height=600 | ||
</youtube> | </youtube> | ||
== '''Epidemiology''' == | == '''Epidemiology''' == | ||
* The prevalence of cutaneous LP is approximately 0.2% to 1% of adults worldwide. | * The prevalence of cutaneous LP is approximately 0.2% to 1% of adults worldwide. | ||
* Oral LP is more common and reported in 1% to 4% of the population. | * Oral LP is more common and reported in 1% to 4% of the population. | ||
* Overall, women are more frequently affected than men at a ratio of 1.5:1, and most cases develop between the ages of 30 and 60. | * Overall, women are more frequently affected than men at a ratio of 1.5:1, and most cases develop between the ages of 30 and 60. | ||
* It is rare in children as they represent less than 5% of all LP patients. | * It is rare in children as they represent less than 5% of all LP patients. | ||
== '''Cause''' == | == '''Cause''' == | ||
* Lichen planus is an [[idiopathic]] disease.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | * Lichen planus is an [[idiopathic]] disease.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | ||
* Its pathogenesis is not fully understood, but it appears to represent a T-cell-mediated [[autoimmune disease]]. | |||
* Its pathogenesis is not fully understood, but it appears to represent a T-cell-mediated [[autoimmune disease]]. | * The prevailing theory is that exposure to an exogenous agent such as a virus, drug, or contact allergen causes alteration of epidermal self-antigens and activation of cytotoxic CD8+ [[T cells]]. | ||
* The prevailing theory is that exposure to an exogenous agent such as a virus, drug, or contact allergen causes alteration of epidermal self-antigens and activation of cytotoxic CD8+ [[T cells]]. | |||
* The '''altered self-antigens cross-react with normal self-antigens found on basal keratinocytes resulting in T-cell targeting and apoptosis'''. | * The '''altered self-antigens cross-react with normal self-antigens found on basal keratinocytes resulting in T-cell targeting and apoptosis'''. | ||
* A variety of agents have been associated with the development of LP, but a particular note has been made of the link with viruses, especially the hepatitis C virus (HCV). | * A variety of agents have been associated with the development of LP, but a particular note has been made of the link with viruses, especially the hepatitis C virus (HCV). | ||
* Oral lichen planus is correlated with contact allergies to a variety of metals found in dental restorations including mercury, copper, and gold. | * Oral lichen planus is correlated with contact allergies to a variety of metals found in dental restorations including mercury, copper, and gold. | ||
* A large number of drugs have been associated with LP, but recurrence of lesions following drug rechallenge is rare. | * A large number of drugs have been associated with LP, but recurrence of lesions following drug rechallenge is rare. | ||
* More commonly associated drugs include [[antimalarials]], ACEIs, [[Thiazide diuretic|thiazide diuretics]], [[NSAIDS|NSAIDs]], [[quinidine]], [[beta-blockers]], [[tumor necrosis factor]] (TNF)-alpha inhibitors, and gold. | * More commonly associated drugs include [[antimalarials]], ACEIs, [[Thiazide diuretic|thiazide diuretics]], [[NSAIDS|NSAIDs]], [[quinidine]], [[beta-blockers]], [[tumor necrosis factor]] (TNF)-alpha inhibitors, and gold. | ||
== '''Signs and symptoms''' == | == '''Signs and symptoms''' == | ||
* Lichen planus can display a variety of lesion types, but the most common presentation is an area of polygon-shaped, itchy, violaceous, flat-topped papules a few millimeters wide. | * Lichen planus can display a variety of lesion types, but the most common presentation is an area of polygon-shaped, itchy, violaceous, flat-topped papules a few millimeters wide. | ||
* This classic presentation is known as The Six Ps of LP: purple, polygonal, planar, pruritic papules, and plaques. | * This classic presentation is known as The Six Ps of LP: purple, polygonal, planar, pruritic papules, and plaques. | ||
== '''Types''' == | == '''Types''' == | ||
Various subtypes of LP exist that display patterns different from the classic presentation. | Various subtypes of LP exist that display patterns different from the classic presentation. | ||
* '''Hypertrophic LP''' is often found on the shins and ankles and is characterized by red, red-brown, or yellow-grey papules and plaques that coalesce with a thickened or verrucous surface. | * '''Hypertrophic LP''' is often found on the shins and ankles and is characterized by red, red-brown, or yellow-grey papules and plaques that coalesce with a thickened or verrucous surface. | ||
* '''Ulcerative LP '''is found on the soles of the feet or between the toes with painful, erosive lesions that make walking difficult. | * '''Ulcerative LP '''is found on the soles of the feet or between the toes with painful, erosive lesions that make walking difficult. | ||
* '''Bullous LP''' appears most often on the legs as small to large tense blisters filled with clear or pale-yellow fluid. | * '''Bullous LP''' appears most often on the legs as small to large tense blisters filled with clear or pale-yellow fluid. | ||
== '''Diagnosis''' == | == '''Diagnosis''' == | ||
* While in the clinic, [[dermoscopy]] allows visualization of Wickham striae in most cases.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | * While in the clinic, [[dermoscopy]] allows visualization of Wickham striae in most cases.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | ||
* A network of white lines with red globules along the periphery is the classic finding. | * A network of white lines with red globules along the periphery is the classic finding. | ||
* Oral LP lesions located near dental restorations should prompt patch testing to determine if an allergy to one of the associated metals exists. | * Oral LP lesions located near dental restorations should prompt patch testing to determine if an allergy to one of the associated metals exists. | ||
* [[Biopsy]] with the microscopic analysis is the most useful tool to confirm the presence of LP. | * [[Biopsy]] with the microscopic analysis is the most useful tool to confirm the presence of LP. | ||
* Lesions have many characteristics as noted previously that typically allow a definitive diagnosis. | * Lesions have many characteristics as noted previously that typically allow a definitive diagnosis. | ||
== '''Treatment''' == | == '''Treatment''' == | ||
* '''Cutaneous LP''' typically clears spontaneously within 1 to 2 years, so treatment is aimed at reducing [[pruritus]] and time to resolution. For limited LP, first-line treatment is superpotent [[Topical steroid therapy|topical steroids]] (clobetasol 0.05%) twice daily for 2 to 4 weeks. | * '''Cutaneous LP''' typically clears spontaneously within 1 to 2 years, so treatment is aimed at reducing [[pruritus]] and time to resolution. For limited LP, first-line treatment is superpotent [[Topical steroid therapy|topical steroids]] (clobetasol 0.05%) twice daily for 2 to 4 weeks. | ||
* For diffuse LP, first-line treatment is daily oral [[corticosteroids]] ([[prednisone]] 30 to 60 mg) tapered over 2 to 6 weeks. If no change is seen, second-line therapy should be considered. Second-line therapy may include [[metronidazole]] (500 mg twice daily for 3 to 8 weeks), [[sulfasalazine]] (500 mg twice daily increased in 500 mg increments every 3 days until 2.5 grams daily is reached, for 3 to 6 weeks), [[isotretinoin]] (10 mg twice daily for 2 months), [[acitretin]] (30 mg daily for 8 weeks), [[PUVA]], UVB, topical calcineurin inhibitors, or methotrexate (15 mg per week for adults, 0.25 mg/kg per week for children). | * For diffuse LP, first-line treatment is daily oral [[corticosteroids]] ([[prednisone]] 30 to 60 mg) tapered over 2 to 6 weeks. If no change is seen, second-line therapy should be considered. Second-line therapy may include [[metronidazole]] (500 mg twice daily for 3 to 8 weeks), [[sulfasalazine]] (500 mg twice daily increased in 500 mg increments every 3 days until 2.5 grams daily is reached, for 3 to 6 weeks), [[isotretinoin]] (10 mg twice daily for 2 months), [[acitretin]] (30 mg daily for 8 weeks), [[PUVA]], UVB, topical calcineurin inhibitors, or methotrexate (15 mg per week for adults, 0.25 mg/kg per week for children). | ||
* Third line treatment may include trimethoprim-sulfamethoxazole, [[griseofulvin]], [[terbinafine]], antimalarials, [[tetracyclines]], [[ciclosporin]], | * Third line treatment may include trimethoprim-sulfamethoxazole, [[griseofulvin]], [[terbinafine]], antimalarials, [[tetracyclines]], [[ciclosporin]], | ||
* [[mycophenolate mofetil]], [[azathioprine]], [[etanercept]], [[adalimumab]], or low-molecular-weight [[heparin]] | * [[mycophenolate mofetil]], [[azathioprine]], [[etanercept]], [[adalimumab]], or low-molecular-weight [[heparin]] | ||
'''Oral LP''' may spontaneously resolve within 5 years, but many cases are chronic and never resolve. | |||
'''Oral LP''' may spontaneously resolve within 5 years, but many cases are chronic and never resolve. | * Treatment-induced remission is typically followed by relapse. | ||
* Treatment-induced remission is typically followed by relapse. | * Thus, asymptomatic oral LP should not be treated as the side-effect burden of treatment is high. | ||
* Thus, asymptomatic oral LP should not be treated as the side-effect burden of treatment is high. | * The goal for treatment of symptomatic oral LP is to heal erosive lesions to reduce pain and allow normal food intake. | ||
* The goal for treatment of symptomatic oral LP is to heal erosive lesions to reduce pain and allow normal food intake. | * Patients should be instructed to avoid spicy or acidic foods as well as alcohol and tobacco as these exacerbate symptoms. | ||
* Patients should be instructed to avoid spicy or acidic foods as well as alcohol and tobacco as these exacerbate symptoms. | |||
* First-line treatment is very high potency [[Topical steroid therapy|topical steroids]] three times daily until remission. | * First-line treatment is very high potency [[Topical steroid therapy|topical steroids]] three times daily until remission. | ||
* Second-line treatment is oral [[corticosteroids]] or application of topical [[calcineurin]] inhibitors. | * Second-line treatment is oral [[corticosteroids]] or application of topical [[calcineurin]] inhibitors. | ||
* Third-line treatment may include [[cyclosporine]], [[azathioprine]], [[mycophenolate mofetil]], or [[methotrexate]]. | * Third-line treatment may include [[cyclosporine]], [[azathioprine]], [[mycophenolate mofetil]], or [[methotrexate]]. | ||
Consideration of '''drug-induced LP''' must always be explored prior to starting therapy. | |||
Consideration of '''drug-induced LP''' must always be explored prior to starting therapy. | |||
* Withdrawal of the suspected drug leading to the gradual disappearance of lesions confirms the diagnosis, although it may take some time for lesions to fully resolve.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | * Withdrawal of the suspected drug leading to the gradual disappearance of lesions confirms the diagnosis, although it may take some time for lesions to fully resolve.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[https://www.ncbi.nlm.nih.gov/books/NBK526126//]. | ||
== '''Prognosis''' == | == '''Prognosis''' == | ||
* Cutaneous LP often clears spontaneously within 1 to 2 years, but residual hyperpigmentation is very common. | * Cutaneous LP often clears spontaneously within 1 to 2 years, but residual hyperpigmentation is very common. | ||
* Oral LP may clear spontaneously within 5 years, but typically it is a chronic disease with a remitting and relapsing course. | * Oral LP may clear spontaneously within 5 years, but typically it is a chronic disease with a remitting and relapsing course. | ||
* Hair loss from LPP is permanent. Drug-induced LP lesions clear slowly after the causative medication is withdrawn. | * Hair loss from LPP is permanent. Drug-induced LP lesions clear slowly after the causative medication is withdrawn. | ||
== '''References''' == | == '''References''' == | ||
<references /> | <references /> | ||
{{Diseases of the skin and appendages by morphology}} | {{Diseases of the skin and appendages by morphology}} | ||
{{Papulosquamous disorders}} | {{Papulosquamous disorders}} | ||
{{oral pathology}} | {{oral pathology}} | ||
{{DEFAULTSORT:Lichen Planus}} | {{DEFAULTSORT:Lichen Planus}} | ||
[[Category:Lichenoid eruptions]] | [[Category:Lichenoid eruptions]] | ||
Latest revision as of 01:27, 8 April 2025

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Lichen planus | |
|---|---|
| File:Lichen Planus (2).JPG | |
| Synonyms | |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Itching, rash, purple papules |
| Complications | Oral lichen planus, scarring |
| Onset | Middle age |
| Duration | Chronic |
| Types | N/A |
| Causes | Autoimmune disease |
| Risks | Hepatitis C, genetic predisposition |
| Diagnosis | Clinical diagnosis, biopsy |
| Differential diagnosis | Psoriasis, eczema, lichen simplex chronicus |
| Prevention | |
| Treatment | Corticosteroids, antihistamines, phototherapy |
| Medication | Topical steroids, oral steroids |
| Prognosis | Generally good, but can be chronic |
| Frequency | 0.1% to 4% of the population |
| Deaths | N/A |
Alternate names[edit]
Actinic LP; Lichen planus actinus; Lichen planus subtropicus; Lichen planus tropicus; Lichenoid melanodermatitis; Summertime actinic lichenoid eruption
Definition[edit]
Lichen planus (LP) is an inflammatory disorder of the skin and mucous membranes with no known cause. It appears as pruritic, violaceous papules and plaques most commonly found on the wrists, lower back, and ankles.
Epidemiology[edit]
- The prevalence of cutaneous LP is approximately 0.2% to 1% of adults worldwide.
- Oral LP is more common and reported in 1% to 4% of the population.
- Overall, women are more frequently affected than men at a ratio of 1.5:1, and most cases develop between the ages of 30 and 60.
- It is rare in children as they represent less than 5% of all LP patients.
Cause[edit]
- Lichen planus is an idiopathic disease.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[1].
- Its pathogenesis is not fully understood, but it appears to represent a T-cell-mediated autoimmune disease.
- The prevailing theory is that exposure to an exogenous agent such as a virus, drug, or contact allergen causes alteration of epidermal self-antigens and activation of cytotoxic CD8+ T cells.
- The altered self-antigens cross-react with normal self-antigens found on basal keratinocytes resulting in T-cell targeting and apoptosis.
- A variety of agents have been associated with the development of LP, but a particular note has been made of the link with viruses, especially the hepatitis C virus (HCV).
- Oral lichen planus is correlated with contact allergies to a variety of metals found in dental restorations including mercury, copper, and gold.
- A large number of drugs have been associated with LP, but recurrence of lesions following drug rechallenge is rare.
- More commonly associated drugs include antimalarials, ACEIs, thiazide diuretics, NSAIDs, quinidine, beta-blockers, tumor necrosis factor (TNF)-alpha inhibitors, and gold.
Signs and symptoms[edit]
- Lichen planus can display a variety of lesion types, but the most common presentation is an area of polygon-shaped, itchy, violaceous, flat-topped papules a few millimeters wide.
- This classic presentation is known as The Six Ps of LP: purple, polygonal, planar, pruritic papules, and plaques.
Types[edit]
Various subtypes of LP exist that display patterns different from the classic presentation.
- Hypertrophic LP is often found on the shins and ankles and is characterized by red, red-brown, or yellow-grey papules and plaques that coalesce with a thickened or verrucous surface.
- Ulcerative LP is found on the soles of the feet or between the toes with painful, erosive lesions that make walking difficult.
- Bullous LP appears most often on the legs as small to large tense blisters filled with clear or pale-yellow fluid.
Diagnosis[edit]
- While in the clinic, dermoscopy allows visualization of Wickham striae in most cases.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[2].
- A network of white lines with red globules along the periphery is the classic finding.
- Oral LP lesions located near dental restorations should prompt patch testing to determine if an allergy to one of the associated metals exists.
- Biopsy with the microscopic analysis is the most useful tool to confirm the presence of LP.
- Lesions have many characteristics as noted previously that typically allow a definitive diagnosis.
Treatment[edit]
- Cutaneous LP typically clears spontaneously within 1 to 2 years, so treatment is aimed at reducing pruritus and time to resolution. For limited LP, first-line treatment is superpotent topical steroids (clobetasol 0.05%) twice daily for 2 to 4 weeks.
- For diffuse LP, first-line treatment is daily oral corticosteroids (prednisone 30 to 60 mg) tapered over 2 to 6 weeks. If no change is seen, second-line therapy should be considered. Second-line therapy may include metronidazole (500 mg twice daily for 3 to 8 weeks), sulfasalazine (500 mg twice daily increased in 500 mg increments every 3 days until 2.5 grams daily is reached, for 3 to 6 weeks), isotretinoin (10 mg twice daily for 2 months), acitretin (30 mg daily for 8 weeks), PUVA, UVB, topical calcineurin inhibitors, or methotrexate (15 mg per week for adults, 0.25 mg/kg per week for children).
- Third line treatment may include trimethoprim-sulfamethoxazole, griseofulvin, terbinafine, antimalarials, tetracyclines, ciclosporin,
- mycophenolate mofetil, azathioprine, etanercept, adalimumab, or low-molecular-weight heparin
Oral LP may spontaneously resolve within 5 years, but many cases are chronic and never resolve.
- Treatment-induced remission is typically followed by relapse.
- Thus, asymptomatic oral LP should not be treated as the side-effect burden of treatment is high.
- The goal for treatment of symptomatic oral LP is to heal erosive lesions to reduce pain and allow normal food intake.
- Patients should be instructed to avoid spicy or acidic foods as well as alcohol and tobacco as these exacerbate symptoms.
- First-line treatment is very high potency topical steroids three times daily until remission.
- Second-line treatment is oral corticosteroids or application of topical calcineurin inhibitors.
- Third-line treatment may include cyclosporine, azathioprine, mycophenolate mofetil, or methotrexate.
Consideration of drug-induced LP must always be explored prior to starting therapy.
- Withdrawal of the suspected drug leading to the gradual disappearance of lesions confirms the diagnosis, although it may take some time for lesions to fully resolve.<ref>Arnold DL, Krishnamurthy K. Lichen Planus. [Updated 2020 Aug 10]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK526126/</ref>[3].
Prognosis[edit]
- Cutaneous LP often clears spontaneously within 1 to 2 years, but residual hyperpigmentation is very common.
- Oral LP may clear spontaneously within 5 years, but typically it is a chronic disease with a remitting and relapsing course.
- Hair loss from LPP is permanent. Drug-induced LP lesions clear slowly after the causative medication is withdrawn.
References[edit]
<references />
| Diseases of the skin and appendages by morphology | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| Papulosquamous disorders | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NIH genetic and rare disease info[edit]
Lichen planus is a rare disease.
| Rare and genetic diseases | ||||||
|---|---|---|---|---|---|---|
|
Rare diseases - Lichen planus
|


